194 related articles for article (PubMed ID: 16570038)
1. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.
Koizumi W; Tanabe S; Saigenji K; Ohtsu A; Boku N; Nagashima F; Shirao K; Matsumura Y; Gotoh M
Br J Cancer; 2003 Dec; 89(12):2207-12. PubMed ID: 14676796
[TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].
Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Nagaba S; Azuma M; Shimoda T; Nishimura K; Nakatani K; Saigenji K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1957-61. PubMed ID: 15570920
[TBL] [Abstract][Full Text] [Related]
5. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Ogata Y; Sasatomi T; Akagi Y; Ishibashi N; Mori S; Shirouzu K
Kurume Med J; 2009; 56(1-2):1-7. PubMed ID: 20103995
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Choi YH; Kim TW; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK
Cancer Chemother Pharmacol; 2011 Oct; 68(4):905-12. PubMed ID: 21290246
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Yamada Y; Yasui H; Goto A; Arai T; Ura T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2003 Dec; 8(6):374-80. PubMed ID: 14663640
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
11. [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Komatsu Y; Yuki S; Miyagishima T; Asaka M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():75-8. PubMed ID: 16897976
[TBL] [Abstract][Full Text] [Related]
12. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani K; Narahara H; Takiuchi H; Tsujinaka T; Satomi E; Gotoh M; Hirao M; Furukawa H; Taguchi T
Oncology; 2005; 69(5):414-20. PubMed ID: 16319513
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Yoshioka T; Kato S; Gamoh M; Chiba N; Suzuki T; Sakayori N; Kato S; Shibata H; Shimodaira H; Otsuka K; Kakudo Y; Takahashi S; Ishioka C
Br J Cancer; 2009 Dec; 101(12):1972-7. PubMed ID: 19920821
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
[TBL] [Abstract][Full Text] [Related]
18. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Yamazaki K; Watanabe M; Suzuki N; Kusano M
Oncology; 2007; 72(1-2):58-63. PubMed ID: 17998791
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Mochiki E; Ohno T; Kamiyama Y; Aihara R; Haga N; Ojima H; Nakamura J; Ohsawa H; Nakabayashi T; Takeuchi K; Asao T; Kuwano H;
Br J Cancer; 2006 Dec; 95(12):1642-7. PubMed ID: 17133268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]